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alcoholic hepatitis: The question is still openTo the Editor:
We read with interest the article by Stewart et al. [1].
The authors concluded that the treatment of severe acute
alcoholic hepatitis (AAH) with antioxidants (AO) alone
or with corticosteroids (C) did not improve survival at 6
months. Combining AO with C is attractive, since exces-
sive TNFa levels in AAH are more damaging on hepato-
cytes when glutathione reserves are depleted by chronic
alcohol intake [2]. The negative results of this work should
not oblige us to hastily abandon this strategy. The study
had several limits: (i) Sample size calculation was based
on the hypothesis of a 40% survival improvement with
AO, which seems to be much too optimistic; (ii) AAH
was only histologically conﬁrmed in 63% of the cases;
(iii) surprisingly, 44% (n = 34/77) of the patients with a
Maddrey scoreP32 were not treated with corticosteroids,
for reasons not speciﬁed; and (iv) two stratiﬁcations (gen-
der and corticosteroids) were applied prior to randomiza-
tion for AO, resulting in eight small groups, with two
without any treatment. Assessment of survival was per-
formed by pooling 34 patients treated by C or not treated,
compared with 36 patients treated with AO or placebo,
plus C or no treatment. This boils down to testing two
hypotheses at the same time (AO vs. C and AO + C vs.
C), which is not appropriate – especially since the C vs.
AO strategy has been shown to be ineﬀective [3]. Hence,we believe that it is still worth performing a study which
compares a combination therapy (C + AO) with C alone
in severe AAH patients.
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Antioxidants plus corticosteroids in the treatment of severe acute
alcoholic hepatitis: The question is still open: Reply
To the Editor:
We would like to thank Nguyen-Khac et al. for their
interest in our article [1] and respond to their points. We
would agree that there is in vitro evidence that would sug-
gest that antioxidants (AO) should be of beneﬁt in vivo.
The result of the trial was disappointing. Though the
numbers were small, we feel that there is little to suggest
that patients beneﬁt from AO at this stage of the disease.
The referenced article byPhillips et al. shows the beneﬁt
of corticosteroids over antioxidants in those patients that
were eligible for corticosteroids [2]. It does not address the
role of antioxidants inpatientswhocannot receive cortico-
steroids and it does not enlighten us as to whether antiox-
idants have a role in addition to corticosteroids.
As suggested we were testing two hypotheses con-
comitantly in our study, but not the ones suggested in
the letter; AO vs placebo in those ineligible for cortico-
steroids and AO + corticosteroids vs. corticosteroids in
those eligible. At no point were we testing the hypothesis
of AO vs. corticosteroids. This would have included two
diﬀerent groups of patients with diﬀerent mortalities;
those that were ineligible for corticosteroids but were
randomized to AO and those that were eligible for cor-
ticosteroids but were randomized to placebo. We feel
that our trial reﬂected the clinical situation where corti-
costeroids are given if possible.
Bleeding or sepsis precluded this in 44% of our pa-
tients. This is not a surprising ﬁgure in our unit.
Our trial was designed to pick up a 40% mortality
reduction. While a smaller reduction in mortality would
require larger numbers to detect, the Kaplan–Meier sur-
vival curves are almost superimposed. The authors sug-
gest a further trial focussing only on patients eligible for
corticosteroids and randomized to receive antioxidants
or placebo. We found the 6-month mortality to be 5/18
(28%) in the steroid only group and 10/20 (50%) in the ste-
roid and antioxidant group. Further, larger trials would
of course help to clarify this lack of beneﬁt, or perhaps
show some advantage toAO treatment.We feel, however,
that given the paucity of new studies in acute severe alco-
holic hepatitis, and considering the mortality in a young
population, that further eﬀorts should focus on treat-
ments more likely to have clinical beneﬁt.
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